CN100390292C - 甲胎蛋白表达细胞的腺病毒载体及其使用方法 - Google Patents
甲胎蛋白表达细胞的腺病毒载体及其使用方法 Download PDFInfo
- Publication number
- CN100390292C CN100390292C CNB988043890A CN98804389A CN100390292C CN 100390292 C CN100390292 C CN 100390292C CN B988043890 A CNB988043890 A CN B988043890A CN 98804389 A CN98804389 A CN 98804389A CN 100390292 C CN100390292 C CN 100390292C
- Authority
- CN
- China
- Prior art keywords
- adenovirus
- afp
- cell
- gene
- tre
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3959797P | 1997-03-03 | 1997-03-03 | |
US09/033,428 | 1998-03-02 | ||
US60/039,597 | 1998-03-02 | ||
US09/033,428 US6254862B1 (en) | 1997-03-03 | 1998-03-02 | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1252840A CN1252840A (zh) | 2000-05-10 |
CN100390292C true CN100390292C (zh) | 2008-05-28 |
Family
ID=21906330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB988043890A Expired - Fee Related CN100390292C (zh) | 1997-03-03 | 1998-03-03 | 甲胎蛋白表达细胞的腺病毒载体及其使用方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US6254862B1 (de) |
EP (1) | EP0972063B1 (de) |
JP (1) | JP2002516568A (de) |
KR (1) | KR20000075924A (de) |
CN (1) | CN100390292C (de) |
AT (1) | ATE385256T1 (de) |
AU (1) | AU745560B2 (de) |
CA (1) | CA2282706C (de) |
DE (1) | DE69839071T2 (de) |
WO (1) | WO1998039465A2 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
US20020068049A1 (en) * | 1998-09-10 | 2002-06-06 | Henderson Daniel R. | Tissue specific adenoviral vectors |
US7011976B1 (en) * | 1997-03-03 | 2006-03-14 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
US6254862B1 (en) * | 1997-03-03 | 2001-07-03 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
US7001764B2 (en) * | 1995-06-27 | 2006-02-21 | Cell Genesys, Inc. | Compositions comprising tissue specific adenoviral vectors |
US6676935B2 (en) * | 1995-06-27 | 2004-01-13 | Cell Genesys, Inc. | Tissue specific adenoviral vectors |
US20060165658A1 (en) * | 1997-03-03 | 2006-07-27 | Little Andrew S | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
WO1999006576A1 (en) * | 1997-08-04 | 1999-02-11 | Calydon, Inc. | A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof |
US6900049B2 (en) * | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
AU2344100A (en) * | 1998-11-18 | 2000-06-05 | Canji, Inc. | Viral vectors with late transgene expression |
US6495130B1 (en) * | 1998-12-30 | 2002-12-17 | Calydon, Inc. | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
US20060024273A1 (en) * | 1998-12-30 | 2006-02-02 | Henderson Daniel R | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
US6627190B2 (en) * | 1999-07-12 | 2003-09-30 | Saint Louis University | Recombinant adenovirus vectors that are replication-competent in tert-expressing cells |
US7589069B1 (en) * | 1999-07-12 | 2009-09-15 | Saint Louis University | Replication-competent anti-cancer vectors |
CA2384814A1 (en) | 1999-09-29 | 2001-04-05 | The Trustees Of The University Of Pennsylvania | Methods for rapid peg-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor |
WO2001070175A2 (en) * | 2000-03-21 | 2001-09-27 | The University Of Virginia Patent Foundation | Osteocalcin promoter directed adenovirus replicaton for therapy |
AU2001245944B2 (en) | 2000-03-24 | 2007-01-18 | Cell Genesys, Inc. | Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof |
US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
US7048920B2 (en) | 2000-03-24 | 2006-05-23 | Cell Genesys, Inc. | Recombinant oncolytic adenovirus for human melanoma |
US6911200B2 (en) * | 2000-03-24 | 2005-06-28 | Cell Genesys, Inc. | Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation |
US6673614B2 (en) | 2000-06-27 | 2004-01-06 | Cell Genesys, Inc. | Rapid methods and kits for detection and semi-quantitation of anti-adenovirus antibody |
WO2003033514A1 (en) | 2001-10-19 | 2003-04-24 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
WO2002068627A2 (en) * | 2001-02-23 | 2002-09-06 | Novartis Ag | Vector constucts |
US20030086903A1 (en) | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
EP1605053A1 (de) * | 2002-03-26 | 2005-12-14 | Oncolytics Biotech Inc. | Verwendung von Adenoviren mit Mutationen in den VA-Genen für die Krebstherapie |
US7364727B2 (en) * | 2002-07-22 | 2008-04-29 | Cell Genesys, Inc. | Metastatic colon cancer specific promoter and uses thereof |
AU2003271730A1 (en) * | 2002-10-15 | 2004-05-04 | Per Sonne Holm | Novel adenoviruses, nucleic acids coding therefor, and use thereof |
US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
US7709224B2 (en) * | 2003-06-03 | 2010-05-04 | Biosante Pharmaceuticals, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
US20050186178A1 (en) * | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
CN100420742C (zh) * | 2003-09-29 | 2008-09-24 | 中国人民解放军军事医学科学院基础医学研究所 | 一种肝癌靶向性溶瘤腺病毒,其制备方法及用途 |
US7482156B2 (en) * | 2003-10-15 | 2009-01-27 | Cell Genesys, Inc. | Hepatocellular carcinoma specific promoter and uses thereof |
DE602004025726D1 (de) * | 2003-11-14 | 2010-04-08 | Genvec Inc | Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc). |
US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
ES2292271B1 (es) * | 2004-05-20 | 2009-02-16 | Proyecto De Biomedicina Cima, S.L. | Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales. |
TWI293307B (en) | 2004-09-30 | 2008-02-11 | Ind Tech Res Inst | A liver-specific chimeric regulatory sequence and use thereof |
DE102005055128B4 (de) * | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
EP1900749A1 (de) * | 2006-09-12 | 2008-03-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nukleinsäuren zur Expression von Polynukleotiden in Säuger-Krebszellen |
WO2008060357A2 (en) * | 2006-09-29 | 2008-05-22 | Canji, Inc. | Methods of polypeptide production |
CN102268456B (zh) * | 2007-04-23 | 2013-02-06 | 深圳益世康宁生物科技有限公司 | 一种Her-2/neu重组腺相关病毒载体及其构建方法与应用 |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993019768A1 (en) * | 1992-04-03 | 1993-10-14 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system |
WO1996017053A1 (en) * | 1994-11-28 | 1996-06-06 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
WO1996021036A2 (en) * | 1994-12-30 | 1996-07-11 | Chiron Viagene, Inc. | Nucleic acid condensing agents with reduced immunogenicity |
WO1996034969A2 (en) * | 1995-05-03 | 1996-11-07 | Canji, Inc. | Gene therapy using replication competent targeted adenoviral vectors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
JP2686819B2 (ja) | 1989-05-01 | 1997-12-08 | 雪印乳業株式会社 | α―フェトプロテイン遺伝子のエンハンサーに結合する蛋白質をコードするDNA |
GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
DE69129897T2 (de) | 1990-10-25 | 1998-12-17 | Clague Pitman Hodgson | Methode des gentransfers mittels retrotransposons |
US5501662A (en) | 1992-05-22 | 1996-03-26 | Genetronics, Inc. | Implantable electroporation method and apparatus for drug and gene delivery |
WO1994026915A1 (en) | 1993-05-10 | 1994-11-24 | The Regents Of The University Of Michigan | Gene transfer into pancreatic and biliary epithelial cells |
EP0705344B8 (de) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vektoren für gentherapie |
BR9407956A (pt) | 1993-10-25 | 1996-11-26 | Canji Inc | Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais |
US5804407A (en) | 1993-11-04 | 1998-09-08 | University Technologies International, Inc. | Method of expressing genes in mammalian cells |
US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US6254862B1 (en) * | 1997-03-03 | 2001-07-03 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
-
1998
- 1998-03-02 US US09/033,428 patent/US6254862B1/en not_active Expired - Fee Related
- 1998-03-03 AT AT98908871T patent/ATE385256T1/de not_active IP Right Cessation
- 1998-03-03 CN CNB988043890A patent/CN100390292C/zh not_active Expired - Fee Related
- 1998-03-03 CA CA002282706A patent/CA2282706C/en not_active Expired - Fee Related
- 1998-03-03 JP JP53867698A patent/JP2002516568A/ja not_active Ceased
- 1998-03-03 WO PCT/US1998/004084 patent/WO1998039465A2/en active IP Right Grant
- 1998-03-03 KR KR1019997008005A patent/KR20000075924A/ko not_active Application Discontinuation
- 1998-03-03 AU AU66796/98A patent/AU745560B2/en not_active Ceased
- 1998-03-03 DE DE69839071T patent/DE69839071T2/de not_active Expired - Fee Related
- 1998-03-03 EP EP98908871A patent/EP0972063B1/de not_active Expired - Lifetime
-
2001
- 2001-07-02 US US09/898,883 patent/US6585968B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993019768A1 (en) * | 1992-04-03 | 1993-10-14 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system |
WO1996017053A1 (en) * | 1994-11-28 | 1996-06-06 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
WO1996021036A2 (en) * | 1994-12-30 | 1996-07-11 | Chiron Viagene, Inc. | Nucleic acid condensing agents with reduced immunogenicity |
WO1996034969A2 (en) * | 1995-05-03 | 1996-11-07 | Canji, Inc. | Gene therapy using replication competent targeted adenoviral vectors |
Also Published As
Publication number | Publication date |
---|---|
CA2282706A1 (en) | 1998-09-11 |
KR20000075924A (ko) | 2000-12-26 |
EP0972063A2 (de) | 2000-01-19 |
WO1998039465A3 (en) | 1998-12-10 |
CA2282706C (en) | 2008-07-22 |
DE69839071D1 (de) | 2008-03-20 |
AU6679698A (en) | 1998-09-22 |
AU745560B2 (en) | 2002-03-21 |
WO1998039465A2 (en) | 1998-09-11 |
US6585968B2 (en) | 2003-07-01 |
US6254862B1 (en) | 2001-07-03 |
DE69839071T2 (de) | 2009-01-22 |
EP0972063B1 (de) | 2008-01-30 |
CN1252840A (zh) | 2000-05-10 |
JP2002516568A (ja) | 2002-06-04 |
ATE385256T1 (de) | 2008-02-15 |
US20020164799A1 (en) | 2002-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100390292C (zh) | 甲胎蛋白表达细胞的腺病毒载体及其使用方法 | |
US11618888B2 (en) | Tumor-selective E1A and E1B mutants | |
JP2002514075A (ja) | 癌胎児性抗原を発現する細胞に特異的なアデノウイルスベクターおよびその使用方法 | |
CA2283231C (en) | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same | |
JP2001515351A (ja) | アンドロゲンレセプターを発現する細胞に特異的なアデノウイルスベクターおよびその使用方法 | |
JP2002525063A (ja) | 細胞状態特異的反応エレメントを含むアデノウイルスベクター及びその使用方法 | |
JP2002330786A (ja) | 抗炎症性ベクター | |
US7011976B1 (en) | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof | |
AU745600B2 (en) | Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof | |
US20060165658A1 (en) | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof | |
EP1918380A2 (de) | Adenovirusvektoren für Alpha-Fötoprotein exprimierende Zellen und Anwendungsverfahren dafür | |
EP1905837A1 (de) | Adenovirusvektoren mit heterologen Transkriptionsregulationselementen und diese verwendende Verfahren | |
EP0968298A2 (de) | Adenovirale vektoren, spezifisch für zellen, die karzinoembryonisches antigen exprimieren, und methoden für ihre verwendung | |
WO2004016652A2 (en) | Mammaglobin promoter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: CELL GENE SYSTEM CO.,LTD. Free format text: FORMER OWNER: CALYDON, INC. |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT AGENT; FROM: HUANG GESHENG; TO: LIU XIAODONG Effective date: 20020123 |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20020123 Address after: American California Agent after: Liu Xiaodong Applicant after: Cell Genesys Inc. Address before: American California Agent before: Huang Gesheng Applicant before: Calydon, Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080528 |